Lisata Therapeutics, Inc. (LSTA) Stock Forecast
LSTA analyst forecast
as of October 17, 2026- Analyst consensus
- Hold 3.00 / 5 from 2 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +288.3% from the latest close
- Next earnings
- November 5, 2026
- 52-week range
- $0.99 – $5.04
LSTA analyst ratings
2 analystsNumber of analysts at each rating.
LSTA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LSTA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$1.09 | −$1.09 | −$1.09 | −$1.91 | +42.9% | 1 |
| Next fiscal year (2027) | −$1.16 | −$1.16 | −$1.16 | −$1.09 | −6.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LSTA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
LSTA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LSTA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$1.02 | −$0.96 | −$0.96 | −$0.96 | −$1.09 | +6.3% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.91 | −$0.66 | −$0.66 | −$0.66 | −$1.16 | +27.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LSTA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LSTA beat in 9 of 11.
What analysts expect from LSTA
2 analysts cover Lisata Therapeutics; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 288.3% above the latest close of $1.03. Analysts expect earnings of −$1.09 per share for 2026, +42.9% from a year earlier. For 2027 the average estimate is −$1.16 per share. Lisata Therapeutics beat the EPS estimate in 9 of the last 11 quarters.
Related: LSTA income statement, LSTA key metrics, LSTA chart. See the LSTA stock overview for the latest quote and news.
LSTA forecast FAQ
What is Lisata Therapeutics's price target?
The average analyst price target for Lisata Therapeutics is $4.00, 288.3% above the latest close of $1.03.
Is Lisata Therapeutics a buy, hold or sell?
Of 2 analysts covering Lisata Therapeutics, 0 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Lisata Therapeutics's EPS forecast?
Analysts forecast −$1.09 per share for 2026 (range −$1.09 to −$1.09); for 2027 the estimate is −$1.16.
When does Lisata Therapeutics report earnings?
Lisata Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
Does Lisata Therapeutics usually beat earnings estimates?
Lisata Therapeutics reported EPS at or above the analyst estimate in 9 of the last 11 quarters.